Kedrion Participates in International Event on Primary Immunodeficiencies
Biennial Meeting of the European Society for Immunodeficiencies (ESID) took place in late October in Prague
Kedrion announces more factual, long-term role in Africa
The company’s efforts try to grant African patients better access to treatments
Investigating inhibitor development in patients with Hemophilia A
Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB
Festival della Salute: conference on self-sufficiency supported by Kedrion
Plasma and plasma-derived products take centre stage at a workshop with all the stakeholders of the Italian Blood System
Counterfeit RhoGAM Ultra-Filtered PLUS used for preventing HDN found in India
Johnson & Johnson Limited has identified counterfeit RhoGAM Ultra-Filtered PLUS in the state of West Bengal and Uttar Pradesh in India. This issue does not involve any other product manufactured or distributed by Ortho Clinical Diagnostics or Kedrion Biopharma India Pvt. Ltd.
Kedrion, one of Italy’s most innovative companies in 2014
The MIT Technology Review Italia’s award given in Bologna in mid-May
5-year unrated EUR 300 million bond successfully launched
The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange
Kedrion Group approves 2013 financial statements
Achieved results of 425 million euros turnover and a 25% profitability
Kedrion collection centers first to be certified in Hungary
Plazmaferezis Állomás Kft achieves international PPTA certification
Award in the US for efforts to support hemophilia patients communities
Kedrion’s Vice-President of North American Commercial Operations is “Man of the Year” for the Hemophilia Association of New Jersey